Significance of adhesion molecules expression for estimation of serous ovarian cancer prognosis

Experimental Oncology

Volumn 35, Issue 3, 2013, Pages 211-218

  Ryabtseva, O D ^a   Lukianova, N Yu ^a   Shmurakov, Yu A ^b   Polishchuk, L Z ^a   Antipova, S V ^c  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

^b Lugansk Regional Clinical Oncology Dispensary ^*  (Ukraine)

^c Lugansk State Medical University   (Ukraine)

Author keywords

Budding; CD44; E cadherin; Immunohistochemical analysis; Malignancy; Morphology; Prognosis; Serous ovarian cancer

Indexed keywords

HERMES ANTIGEN; UVOMORULIN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CELL ADHESION; CELL DIFFERENTIATION; CELL STRUCTURE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM METASTASIS; PHENOTYPE; PROTEIN EXPRESSION;

AGED; ANTIGENS, CD44; CADHERINS; CELL ADHESION MOLECULES; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL;

EID: 84892144348     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Parkin FJ, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-81
2. Polishchuk LZ, Lukianova NYu, Ryabtzeva OD, Chekhun VF. Value of serous cancer malignancy grade with registration of VEGF and Ki-67 in tumor cells. Oncology 2012; 14: 265-71 (in Russian)
3. Buchynska LG, Nesina IP, Yurchenko NP, et al. Expression of p53, p21waf1/cip1, p16ink4a and Ki-67 proteins in serous ovarian tumors. Exp Oncol 2007; 29: 49-53
4. Zagouri F, Dimopoulos MA, Bournakis E, et al. Molecular markers in epithelial ovarian cancer: their role in prognosis and therapy. Eur J Gynaecol Oncol 2010; 31: 268-77
5. Sylvia MT, Kumar S, Dasari P. The expression of immunohistochemical markers estrogen receptor, progesterone receptor, Her-2-neu, p53 and Ki-67 in epithelial ovarian tumors and its correlation with clinicopathologic variables.Indian J Pathol Microbiol 2012; 55: 33-7
6. Ponta H, Sherman L, Herrlich P. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003; 4: 33-45
7. Nelson WJ. Regulation of cell-cell adhesion by the cadherin- catenin complex. Biochem Soc Trans 2008; 36: 149-55
8. Montgomery N, Hill A, McFarlane S, et al. CD44 enhances invasion of basal-like breast cancer cells by upregulating serine protease and collagen-degrading enzymatic expression and activity. Breast Cancer Res 2012; 14: 1-19
9. Gumbiner BM. Regulation of cadherin adhesive activity. J Cell Biol 2000; 148: 399-404
10. Kovacs EM, Ali RG, McCormack AJ, Yap AS. Ecadherin homophilic ligation directly signals through Rac and phosphatidylinositol 3-kinase to regulate adhesive contacts. J Biol Chem 2002; 277: 6708-18
11. Perrais M, Chen X, Perez-Moreno M, Gumbiner BM. E-cadherin homophilic ligation inhibits cell growth and epidermal growth factor receptor signaling independently of other cell interactions. Mol Biol Cell 2007; 18: 2013-25
12. van Roy F, Berx G. The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci 2008; 65: 3756-88
13. Cheng JC, Auersperg N, Leung PC. EGF-induced EMT and invasiveness in Serous Borderline Ovarian Tumor Cells: A possible step in the transition to low-grade serous carcinoma cells? PLoS One 2012; 7: 1-9
14. Kemler R. From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion. TrendsGenet 1993; 9: 317-21
15. Wheelock MJ, Shintani Y, Maeda M, et al. Cadherin switching. J Cell Sci 2008, 121: 727-35
16. Horiuchi A, Konishi I. Mechanism of ovarian cancer metastasis changes in E- cadherin expression. Nihon Rinsho 2004; 62: 463-6
17. Sawada K, Mitra AK, Radjabi AR, et al. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res 2008; 68: 2329-39
18. Naor D, Sionov RV, Ish-Shalom D. CD44, structure, function, and association with the malignant process. Adv Cancer Res 1997; 71: 241-319
19. Iczkowski KA. Cell adhesion molecule CD44: its functional roles in prostate cancer. Am J Transl Res 2010; 3: 1-7
20. Lopez JI, Camenisch TD, Stevens MV, et al. CD44 attenuates metastatic invasion during breast cancer progression. Cancer Res 2005; 65: 6755-63
21. Ghaffarzadehgan K, Jafarzadeh M, Raziee HR, et al. Expression of cell adhesion molecule CD44 in gastric adenocarcinoma and its prognostic importance. World J Gastroenterol.2008; 14: 6376-81
22. Ko YH, Won HS, Jeon EK, et al. Prognostic significance of CD44s expression in resected non-small cell lung cancer. BMC Cancer 2011; 7: 340
23. Alvero AB, Chen R, Fu HH, et al. Molecular phenotyping of human ovarian cancer stem cells unravel the mechanisms for repair and chemo-resistance. Cell Cycle 2009; 8 : 158-66
24. Da Cunha CB, Oliveira C, Wen X, et al. De novo expression of CD44 variants in sporadic and hereditary gastric cancer. Lab Invest 2010; 90: 1604-14
25. Palagani V, El Khatib M, Krech T, et al. Decrease of CD44-positive cells correlates with tumor response to chemotherapy in patients with gastrointestinal cancer. Anticancer Res. 2012; 32: 1747-55
26. Shukla SJ, Duan S, Wu X, et al. Whole-genome approach implicates CD44 in cellular resistance to carboplatin.Human Genomics 2009; 3: 128-42
27. Takaishi S, Okumura T, Tu S, et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009; 27: 1006-20
28. Wang Z, Shi Q, Wang Z, et al. Clinicopathologic correlation of cancer stem cell markers CD44, CD24, VEGF and HIF-1α in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study. Pathol Res Pract 2011; 207: 505-13
29. Jaggupilli A, Elkord E. Significance of CD44 and CD24 as cancer stem cell markers. Clin Develop Immunol 2012. Article ID 708036, 11 pages
30. Steffensen KD, Alvero AB, Yang Y, et al. Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. J Oncol 2011; doi: 10.1155/2011/620523
31. Louderbough JMV, Schroeder JA. Understanding the dual nature of CD44 in breast cancer progression. Mol Cancer Res 2011; 9: 1573-86
32. Herrlich P, Morrison H, Sleeman J, et al. CD44 acts both as a growth- and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann N Y Acad Sci USA2000; 910: 106-18
33. Alvero AB, Chen R, Fu HH, et al. Molecular phenotyping of human ovarian cancer stem cells.unravel the mechanisms for repair and chemo-resistance. Cell Cycle 2009; 1: 158-66
34. Ohtsuki K, Koyama F, Tamura T, et al. Prognostic value of immunohistochemical analysis of tumor budding in colorectal carcinoma. Anticancer Res 2008; 28: 1831-6
35. Mitrovic B, Schaeffer DF, Riddell RH, Kirsch R. Tumor budding in colorectal carcinoma: time to take notice. Mol Pathol 2012; 25: 1315-25
36. Wang C, Huang H, Huang Z, et al. Tumor budding correlates with poor prognosis and epithelial-mesenchymal transition in tongue squamous cell carcinoma. J Oral Pathol Med 2011; 40: 545-51
37. Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget 2010; 1: 651-61
38. Zagorianakou N, Stefanou D, Makrydimas G, et al. CD44s expression, in benign, borderline and malignant tumors of ovarian surface epithelium. Correlation with p53, steroid receptor status, proliferative indices (PCNA, MIB1) and survival. Anticancer Res 2004; 24: 1665-70
39. Bourguignon LY, Peyrollier K, Xia W, Gilad E. Hyaluronan- CD44 interaction activates stem cell marker Nanog, Stat- 3-mediated MDR1 gene expression, and ankyrin- regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 2008; 283: 17635-51
40. Vicente-Dueñas C, Gutiérrez de Diego J, Rodríguez FD, et al. The role of cellular plasticity in cancer development. Curr Med Chem 2009; 16: 3676-85
41. Patra SK, Deb M, Patra A. Molecular marks for epigenetic identification of developmental and cancer stem cells. Clin Epigenetics 2011; 2: 27-53
42. Voutilainen KA, Anttila MA, Sillanpää SM. Prognostic significance of E-cadherin- catenin complex in epithelial ovarian cancer. J Clin Pathol 2006; 59: 460-67
43. Sillanpää S, Anttila MA, Voutilainen K, et al. CD44 expression indicates favorable prognosis in epithelial ovarian cancer. Clin Cancer Res 2003 ; 9: 5318-24
44. Ross JS, Sheehan CE, William SS, et al. Decreased CD44 standard form expression correlates with prognostic variables in ovarian carcinomas. Am J Clin Pathol 2001; 116: 122-8
45. Zhou D-h, Liu Y-x, Xue Y-h. Expression of CD44v6 and its association with prognosis in epithelial ovarian carcinomas. Pathol Res Internat 2012; Article ID 908206, 5 pages
46. Dahl KDC, Symowicz J, Ning Y, et al. Matrix metalloproteinase 9 is a mediator of epidermal growth factordependent E-cadherin loss in ovarian carcinoma cells. Cancer Res 2008; 68: 4606-13
47. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283: 14910-4
48. Yuecheng Y, Hongmei L, Xiaoyan X. Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer. Clin Exp Metastasis 2006, 23: 65-74
49. Koensgen D, Freitag C, Klaman I, et al. Expression and localization of E-Cadherin in epithelial ovarian cancer. Anticancer Res 2010; 30: 2525-30
50. Nakshatri H, Srour EF, Badve S. Breast cancer stem cells and intrinsic subtypes: controversies rage on. Curr Stem Cell Res Ther 2009; 4: 50-60